Pulmonary Artery Catheter in Cardiogenic Shock Trial
This study is looking at whether using a Pulmonary Artery Catheter (PAC) early on can help patients with cardiogenic shock (a severe form of heart failure where your heart can't pump enough blood to meet your body's needs). The PAC is a diagnostic tool that helps doctors monitor heart pressures and function. Researchers want to see if using the PAC early leads to fewer deaths in the hospital compared to standard care without early PAC use. You might be able to join if you are between 18 and 90 years old and have heart failure with reduced pumping ability (LVEF ≤40%). The study will be considered successful if early PAC use results in fewer in-hospital deaths.
- Study design
- This is a randomized study, meaning participants are assigned by chance to different groups. It plans to enroll at least 400 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main outcome is measured at the length of your hospital stay, which is an average of 30 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pulmonary Artery Catheter in Cardiogenic Shock Trial
At a glance
Conditions
NCT05485376
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Tufts Medical Center
Boston, Massachusettsstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Navin K Kapur, MD · PRINCIPAL_INVESTIGATOR · [email protected]
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants who die in the hospitalLength of stay in hospital, an average of 30 days